<DOC>
<DOCNO>EP-0640587</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31155	A61K31155	A61K31185	A61K31185	A61P900	A61P900	A61P910	C07C27700	C07C27708	C07C27900	C07C27920	C07C27922	C07C31100	C07C31137	C07C31500	C07C31504	C07C31700	C07C31732	C07C31744	C07C32300	C07C32365	C07C32367	C07D23300	C07D23360	C07D29500	C07D29510	C07D295155	C07D52100	C07D52100	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61P	A61P	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61P9	A61P9	A61P9	C07C277	C07C277	C07C279	C07C279	C07C279	C07C311	C07C311	C07C315	C07C315	C07C317	C07C317	C07C317	C07C323	C07C323	C07C323	C07D233	C07D233	C07D295	C07D295	C07D295	C07D521	C07D521	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
There are described diacyl-substituted guanidines of the formula I   
<
IMAGE
>
  where     X(1) and X(2) are 
<
IMAGE
>
     T1 is zero, 1, 2, 3 or 4, R(A) and R(B) are hydrogen, Hal, CN, OR(106), (O)(cyclo)(fluoro)alkyl, NR(107)R(108), phenyl or benzyl, or   X(1) and X(2) are 
<
IMAGE
>
     T2a and T2b independently of one another are zero, 1 or 2, where the double bond can have the (E) or (Z) configuration  or   X(1) and X(2) are 
<
IMAGE
>
    and their pharmaceutically tolerable salts. They are outstandingly suitable as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and also for the treatment of angina pectoris, where they also preventively inhibit or greatly decrease the pathophysiological processes in the formation of ischaemically induced damage, in particular in the initiation of ischaemically induced cardiac arrhythmias. Because of their protective actions against pathological hypoxic and ischaemic situations, the compounds of the formula I according to the invention can be used, on account of inhibition of the cellular Na
<
+
>
/H
<
+
>
 exchange mechanism, as medicaments for the treatment of all acute or chronic damage caused by ischaemia or diseases primarily or secondarily induced thereby.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOECHST AG
</APPLICANT-NAME>
<APPLICANT-NAME>
HOECHST AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ALBUS UDO DR
</INVENTOR-NAME>
<INVENTOR-NAME>
CRAUSE PETER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KLEEMANN HEINZ-WERNER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
LANG HANS-JOCHEN DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHOLZ WOLFGANG DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHWARK JAN-ROBERT DR
</INVENTOR-NAME>
<INVENTOR-NAME>
WEICHERT ANDREAS DR
</INVENTOR-NAME>
<INVENTOR-NAME>
ALBUS, UDO DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
CRAUSE, PETER DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KLEEMANN, HEINZ-WERNER DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
LANG, HANS-JOCHEN DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHOLZ, WOLFGANG DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHWARK, JAN-ROBERT DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
WEICHERT, ANDREAS DR.
</INVENTOR-NAME>
</INVENTORS>
</TEXT>
</DOC>
